ExpreS2ion Biotech Announces Grant of US Patent

Today, June 21, 2016, ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion Biotech") announce that its fundamental S2 vector system patent, entitled “Improved Protein Expression System”, has issued in the U.S.A. with patent expiry August 16, 2032. This follows a recent notice of allowance for the patent in the Republic of Korea. The patent has also been granted in Japan, Australia and China, and has been validated in a number of EU countries following approval by the European Patent Office.

Patent information

The patent “Improved protein expression system” covers the ExpreS2 platform in its entirety and has been filed in 15 different countries covering the company’s major markets.

CEO Steen Klysner comments
“Having the ExpreS2 platform protected by patents in all major constitutes an important part of ExpreS2ion Biotech’s future value creation and business model. Getting the patent issued in the US, which is still the largest market for vaccine technology, is of course an important step and necessary step".


For further information , please contact:

Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2-platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.


Tags:

About Us

ExpreS2ion Biotech Holding AB, with company register number 559033-3729, has through the wholly owned Danish subsidiary ExpreS2ion Biotechnologies ApS, developed a platform technology enabling cost effective and robust production of complex proteins for the development of vaccines and diagnostics for e.g. Malaria and Zika. Since foundation in 2010, the subsidiary has used its patented ExpreS2 platform to produce more than 200 proteins in collaboration with research institutions and biopharmaceutical companies, with an efficiency and success rate superior to competing technologies.

Subscribe